We read with great interest the recent contribution of Dr. Kitta et al. in their study,
entitled “Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor
agonist, on lower urinary tract function in children and adolescents with overactive
bladder” [
[1]
]. They showed that treatment with vibegron significantly improved clinical and urodynamic
parameters of pediatric OAB with no adverse effects. However, we would like to contribute
some points regarding their paper.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Pediatric UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder.J Pediatr Urol. 2022; (S1477–5131(22)316-323)
- The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the International Children's Continence Society.Neurourol Urodyn. 2016; 35: 471-481
- Stepwise treatment for overactive bladder is prudent.Can Urol Assoc J. 2017; 11: S80
- Definitions, indications and practice of urotherapy in children and adolescents: - a standardization document of the International Children's Continence Society (ICCS).J Pediatr Urol. 2021; 17: 172-181
- Treatment of daytime urinary incontinence: a standardization document from the International Children's Continence Society.Neurourol Urodyn. 2017; 36: 43-50
Article info
Publication history
Published online: September 21, 2022
Accepted:
September 3,
2022
Received:
August 27,
2022
Identification
Copyright
© 2022 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladderJournal of Pediatric UrologyVol. 18Issue 5
- PreviewIdiopathic overactive bladder (OAB) is defined as an urgency symptom with or without urge incontinence, which is not due to known neurological abnormalities. Since children present with variable symptoms, pediatric nonneurogenic idiopathic OAB is a condition that is difficult to diagnose and treat. Although there are few reports on bladder function in pediatric patients compared to adult patients, it can be useful for diagnosis. Antimuscarinic therapy is the pharmacological mainstay of OAB management.
- Full-Text
- Preview
